GlassScriptPhysician profile
Garrett P Yam
NPI 1811146970
$8,964.65
in general payments reported to CMS, 2019-2025
47 companies · $1,739 in 2025
The $1,739 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $991 · 2021: $1,016 · 2022: $1,551 · 2023: $1,392 · 2024: $1,461 · 2025: $1,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,891 · Gift: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,891.48 |
| Gift | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,568.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $1,192.55 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sekisui Diagnostics LLC | $1,090.00 | 2022-2025 | |
| Abbvie INC. | $551.48 | 2020-2025 | Vraylar, Creon, Linzess |
| Kowa Pharmaceuticals America, INC. | $537.76 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Novo Nordisk INC | $474.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Ibsa Pharma INC. | $309.89 | 2020-2025 | Licart, Tirosint, Flector |
| Pfizer INC. | $286.99 | 2019-2025 | |
| Amarin Pharma, INC. | $246.95 | 2020-2021 | |
| Shield Therapeutics INC | $217.60 | 2023-2024 | Accrufer |
| Lilly USA, LLC | $171.69 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.97 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $135.38 | 2019-2024 | |
| Hologic Sales and Service, LLC | $127.38 | 2022-2025 | Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $122.56 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $122.36 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.43 | 2019-2021 | |
| Exact Sciences Corporation | $110.20 | 2023-2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $107.93 | 2019-2021 | |
| Amgen INC. | $106.73 | 2023-2025 | Krystexxa, Repatha, Otezla |
| Gilead Sciences, INC. | $105.87 | 2021-2023 | |
| Dexcom, INC. | $95.53 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $89.64 | 2023 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $82.21 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Sanofi-Aventis U.S. LLC | $81.62 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $75.24 | 2019-2022 | |
| Allergan, INC. | $71.07 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.91 | 2019 | |
| Sanofi Pasteur INC. | $57.74 | 2023-2024 | |
| Seqirus USA INC | $57.45 | 2019-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Phathom Pharmaceuticals, INC. | $47.70 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $45.22 | 2023-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $41.20 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.01 | 2022 | |
| Boston Scientific Corporation | $35.53 | 2023 | Watchman |
| Cranial Technologies, INC | $31.67 | 2024 | Doc Band |
| Medtronic, INC. | $29.85 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $24.56 | 2023 | Evkeeza |
| Mylan Specialty L.P. | $17.66 | 2022 | |
| Biogen, INC. | $17.29 | 2024 | Skyclarys |
| Ironwood Pharmaceuticals, INC | $16.68 | 2020 | |
| Axsome Therapeutics, INC. | $16.27 | 2025 | Auvelity |
| Jazz Pharmaceuticals INC. | $15.42 | 2020 | |
| Linus Health, INC. | $13.70 | 2024 | Core Cognitive Evaluation |
| Viatris Specialty LLC | $13.57 | 2025 | Yupelri |
| Redhill Biopharma INC. | $12.48 | 2020 | |
| Nabriva Therapeutics, Plc | $11.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Yam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.